The Diflucan Partnership Program donates treatments for 2 opportunistic fungal infections associated with HIV and AIDS (cryptococcal meningitis and esophageal candidiasis) free of charge to government and nongovernmental organizations (NGOs) in developing countries around the world with an HIV and AIDS prevalence of greater than 1%.
First launched in South Africa in 2000, the Diflucan Partnership Program started as a 2-year program, but was later expanded to developing countries across the globe. From providing face-to-face training and distributing program materials to healthcare professionals to help improve patient management and medicine distribution to developing on-line training modules to support the diagnosis and treatment of cryptococcal meningitis and esophageal candidiasis, prevention treatment of AIDS-related opportunistic infection is often a crucial part of care for people living with HIV and AIDS.
Our work providing treatment for these AIDS-related fungal infections could not be done without our implementing partners. We partner with more than 100 institutions, including both governments and NGOs, who provide expertise and contribute to executing the objective of the Diflucan Partnership Program. Collaborating with nonprofit organizations also helps to expand their global impact so that more communities in need access the healthcare they deserve. Our partners include Direct Relief (DR), International Dispensary Association (IDA), governments and nongovernmental organizations (NGOs).
Since 2000, the Diflucan Partnership Program has donated over 106 million Diflucan® (fluconazole) treatments with a total value of more than $1.8 billion to more than 6,000 sites in 63 countries across Africa, Asia, the Caribbean, and Latin America.